RxDoctor Payments Data

Catherine Davis, MD

Internal Medicine · Santa Rosa, CANPI 1497748776

Payments from drug & device makers

$1,736in general payments, 2019–2025

Across 93 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$479
  • Boehringer Ingelheim$188
  • Amgen$168
  • Tandem Diabetes Care, Inc.$135
  • Novo Nordisk$87
  • Johnson & Johnson$80
  • plus $599 from 14 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,71699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,736 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$34,702
Medicare patients
101
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$323,068
JardianceEmpagliflozin109$157,578
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/749$80,300
MounjaroTirzepatide31$51,652
TrulicityDulaglutide34$47,024
TradjentaLinagliptin40$42,353
Tresiba Flextouch U-200Insulin Degludec44$39,396
Tresiba Flextouch U-100Insulin Degludec47$30,812
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$28,587
FarxigaDapagliflozin Propanediol30$22,733
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$18,789
Fiasp FlextouchInsulin Aspart (Niacinamide)16$18,670
Victoza 3-PakLiraglutide14$16,582
Humalog Kwikpen U-100Insulin Lispro54$13,185
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$10,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$87$330,705201 claims
Boehringer IngelheimJardiance, Tradjenta$188$199,931149 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$69$109,195118 claims
AstraZenecaFarxiga$56$22,73330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →